CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Qsam Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Qsam Biosciences Inc
9442 CAPITAL OF TEXAS HWY N
PLAZA 1, SUITE 500
Phone: (512) 343-4558p:512 343-4558 AUSTIN, TX  78759  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 5/3/2024.
This company ceased filing statements with the SEC on 5/2/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
QSAM Biosciences, Inc. is developing nuclear medicines for the treatment of cancer and related diseases. The Company’s technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage bone targeting radiopharmaceutical developed by IsoTherapeutics Group, LLC. Iso Therapeutics Group LLC also developed a commercial radiopharmaceutical on the market, Quadramet (Samarium-153 EDTMP), which is indicated for pain palliation. CycloSam consists of a combination of the radioactive isotope Samarium-153 with a chelating agent, DOTMP (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylenephosphonic acid). Its combination delivers a radioactive dose to sites of bone mineral turnover, such as bone cancers and tumors. CycloSam has a physical half-life of approximately 46 hours and emits both medium-energy beta particles, which produce the therapeutic effect and gamma photons that make it possible to take images of the skeleton and locate and characterize the size and nature of tumors.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes-Yes

Industries
SIC Code Description
2842 Specialty cleaning, polishing, and sanitation preparations
7389 Business services, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board C. RichardPiazza 75 11/6/2020 11/6/2020
Chief Executive Officer, Director Douglas R.Baum 56 11/6/2020 1/16/2020
Chief Financial Officer AdamKing 37 3/3/2022 12/6/2021
3 additional Officers and Directors records available in full report.

Business Names
Business Name
AnPath Acquisition Sub, Inc.
Anpath Group, Inc.
Earth Property Holdings LLC
George B. Wittmer Associates Inc.
Organics “By Gosh”
QSAM Therapeutics, Inc.

General Information
Number of Employees: 4 (As of 12/31/2023)
Outstanding Shares: 2,222 (As of 5/3/2024)
Shareholders: 342
Stock Exchange: OTC
Federal Tax Id: 201602779
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024